摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(3,3-二氟吡咯烷-1-基)哌啶双盐酸盐 | 1061682-67-4

中文名称
4-(3,3-二氟吡咯烷-1-基)哌啶双盐酸盐
中文别名
——
英文名称
4-(3,3-Difluoropyrrolidin-1-yl)piperidine
英文别名
——
4-(3,3-二氟吡咯烷-1-基)哌啶双盐酸盐化学式
CAS
1061682-67-4
化学式
C9H16F2N2
mdl
——
分子量
190.23
InChiKey
HLHFAPNXTVOVGE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    230.2±40.0 °C(Predicted)
  • 密度:
    1.14±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    15.3
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] TRPV4 ANTAGONISTS<br/>[FR] ANTAGONISTES DE TRPV4
    申请人:GLAXOSMITHKLINE LLC
    公开号:WO2011119701A1
    公开(公告)日:2011-09-29
    The present invention relates to quinoline analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    本发明涉及喹啉类似物、含有它们的药物组合物以及它们作为TRPV4拮抗剂的用途。
  • [EN] FACTOR XI ACTIVATION INHIBITORS<br/>[FR] INHIBITEURS D'ACTIVATION DU FACTEUR XI
    申请人:MERCK SHARP & DOHME
    公开号:WO2021202254A1
    公开(公告)日:2021-10-07
    The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XI activation inhibitors.
    本发明提供了一种公式(I)的化合物,以及包含一种或多种所述化合物的制药组合物,并且提供了使用所述化合物治疗或预防血栓、栓塞、高凝状态或纤维化变化的方法。这些化合物是选择性因子XI激活抑制剂。
  • TRPV4 ANTAGONISTS
    申请人:Brooks Carl A.
    公开号:US20130012499A1
    公开(公告)日:2013-01-10
    The present invention relates to quinoline analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    本发明涉及喹啉类似物,包含它们的制药组合物以及它们作为TRPV4拮抗剂的用途。
  • 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders
    申请人:JANSSEN PHARMACEUTICALS, INC.
    公开号:US20170333426A1
    公开(公告)日:2017-11-23
    The present invention relates to methods of treating various central nervous system disorders using novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.
  • US8658636B2
    申请人:——
    公开号:US8658636B2
    公开(公告)日:2014-02-25
查看更多